
Alicia Gutiérrez-Valencia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8830075/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Use of Transient Elastometry for Assessing Liver Fibrosis in Patients with HIV and Hepatitis C Virus Coinfection. Clinical Infectious Diseases, 2007, 45, 969-974.	5.8	178
2	Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection. Cellular and Molecular Immunology, 2021, 18, 2128-2139.	10.5	81
3	Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients. Journal of Infectious Diseases, 2018, 218, 624-632.	4.0	44
4	Stepped-Dose Versus Full-Dose Efavirenz for HIV Infection and Neuropsychiatric Adverse Events. Annals of Internal Medicine, 2009, 151, 149.	3.9	40
5	Lopinavir Plasma Concentrations and Virological Outcome with Lopinavir-Ritonavir Monotherapy in HIV-1-Infected Patients. Antimicrobial Agents and Chemotherapy, 2013, 57, 3746-3751.	3.2	20
6	Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy. Aids, 2014, 28, 201-208.	2.2	15
7	Enterococcus faecalis Endocarditis and Outpatient Treatment: A Systematic Review of Current Alternatives. Antibiotics, 2020, 9, 657.	3.7	15
8	Darunavir Cmin and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients. Antiviral Therapy, 2014, 19, 443-447.	1.0	14
9	Differential Effects of Viremia and Microbial Translocation on Immune Activation in HIV-Infected Patients Throughout Ritonavir-Boosted Darunavir Monotherapy. Medicine (United States), 2015, 94, e781.	1.0	14
10	Viral Kinetics in Semen With Different Antiretroviral Families in Treatment-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Trial. Clinical Infectious Diseases, 2017, 65, 551-556.	5.8	14
11	Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1β, Early Predictors of Severe COVID-19. Microorganisms, 2021, 9, 2259.	3.6	14
12	Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment. PLoS ONE, 2018, 13, e0205777.	2.5	13
13	Efficacy and Safety of Pegylated Interferon plus Ribavirin in HIV and Hepatitis C Virus–Coinfected Patients with Advanced Immunosuppression. Clinical Infectious Diseases, 2009, 49, e84-e91.	5.8	12
14	Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2012, 67, 681-684.	3.0	11
15	Fetuinâ€A, interâ€Î±â€ŧrypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes. Clinical and Translational Medicine, 2022, 12, e704.	4.0	11
16	Ampicillin Plus Ceftriaxone Combined Therapy for Enterococcus faecalis Infective Endocarditis in OPAT. Journal of Clinical Medicine, 2022, 11, 7.	2.4	11
17	Role of Ritonavir in the Drug Interactions Between Telaprevir and Ritonavir-Boosted Atazanavir. Clinical Infectious Diseases, 2014, 58, 268-273.	5.8	8
18	Brief Report: Response to Hepatitis A Virus Vaccine in HIV-Infected Patients Within a Retrospective, Multicentric Cohort: Facing Hepatitis A Outbreaks in the Clinical Practice. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, e1-e5.	2.1	8

#	Article	IF	CITATIONS
19	Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	8
20	Mesenchymal stromal cells in human immunodeficiency virusâ€infected patients with discordant immune response: Early results of a phase I/II clinical trial. Stem Cells Translational Medicine, 2021, 10, 534-541.	3.3	8
21	Deciphering the quality of SARSâ€CoVâ€2 specific Tâ€cell response associated with disease severity, immune memory and heterologous response. Clinical and Translational Medicine, 2022, 12, e802.	4.0	8
22	The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype. Aids, 2013, 27, 1941-1947.	2.2	6
23	Higher Activation in CD4 ⁺ T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy. AIDS Research and Human Retroviruses, 2016, 32, 6-11.	1.1	6
24	Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions. Vaccine, 2019, 37, 2758-2763.	3.8	6
25	Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial. Clinical Microbiology and Infection, 2022, 28, 1151.e9-1151.e16.	6.0	6
26	Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations. Journal of the International AIDS Society, 2018, 21, e25072.	3.0	5
27	Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw487.	3.0	4
28	Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?. Journal of Antimicrobial Chemotherapy, 2020, 75, 200-207.	3.0	4
29	Telaprevir and Ribavirin Interaction: Higher Ribavirin Levels Are Not Only Due to Renal Dysfunction during Triple Therapy. Antimicrobial Agents and Chemotherapy, 2015, 59, 3257-3262.	3.2	3
30	No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients. PLoS ONE, 2018, 13, e0203452.	2.5	3
31	Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C Virus. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	3
32	Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients. PLoS ONE, 2012, 7, e48959.	2.5	2
33	PDA-Based Glyconanomicelles for Hepatocellular Carcinoma Cells Active Targeting Via Mannose and Asialoglycoprotein Receptors. ACS Applied Bio Materials, 2021, 4, 4789-4799.	4.6	2
34	HIV-1 p24 and CD4 + T cell count during boosted protease-inhibitor monotherapy in HIV-infected patients. Enfermedades Infecciosas Y MicrobiologAa ClAnica, 2017, 35, 174-178.	0.5	1
35	Incidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapy. Annals of Hematology, 2019, 98, 1953-1959.	1.8	1
36	Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?. Medicine (United States), 2015, 94, e1743.	1.0	0

#	Article	IF	CITATIONS
37	Early initiation of antiretroviral therapy: debate over?. Lancet Infectious Diseases, The, 2016, 16, 769.	9.1	0
38	Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients. PLoS ONE, 2022, 17, e0269875.	2.5	0